“A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis”., J of Skin, vol. 3, p. S18, Nov. 2019, doi: 10.25251/skin.3.supp.18.